tiprankstipranks
Advertisement
Advertisement

Cresco Labs Grows Cash Flow and Margins Despite 2025 Impairment Charges

Story Highlights
  • Cresco Labs grew 2025 revenue to $656 million, improved profitability metrics and cash generation, and maintained leading share in key cannabis markets while keeping a sizable cash position alongside its debt load.
  • Fourth-quarter results showed higher margins and strong adjusted EBITDA and cash flow, as Cresco absorbed significant non-cash impairment charges and positioned itself to benefit from industry consolidation and possible regulatory shifts.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cresco Labs Grows Cash Flow and Margins Despite 2025 Impairment Charges

Claim 55% Off TipRanks

Cresco Labs ( (TSE:CL) ) has shared an announcement.

Cresco Labs reported full-year 2025 revenue of $656 million, gross profit of $325 million and adjusted EBITDA of $157 million, while generating $73 million in operating cash flow and $38 million in free cash flow. The company reduced adjusted SG&A, maintained leading market share in key states, and ended the year with $91 million in cash and $330 million in debt on its balance sheet.

In the fourth quarter, Cresco Labs delivered $162 million in revenue, a 52.2% adjusted gross margin and $40 million in adjusted EBITDA, alongside $27 million in operating cash flow. Despite a net loss driven largely by non-cash impairment charges tied to its New York and California operations, management emphasized improved margins, strengthened cash generation and a strategy to capitalize on industry consolidation and potential federal reforms.

The most recent analyst rating on (TSE:CL) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.

Spark’s Take on TSE:CL Stock

According to Spark, TipRanks’ AI Analyst, TSE:CL is a Neutral.

Cresco Labs’ overall stock score is primarily impacted by its financial performance challenges, including declining revenues and high leverage. Technical analysis shows moderate strength, while valuation remains weak due to negative profitability metrics. The earnings call provided some positive insights into strategic expansions and debt refinancing, but ongoing market challenges and operational adjustments weigh on the outlook.

To see Spark’s full report on TSE:CL stock, click here.

More about Cresco Labs

Cresco Labs Inc. is a U.S.-based cannabis company that leads the market in branded cannabis products and operates Sunnyside retail dispensaries. The company focuses on building a cash-generative, multi-state platform with leading brand share in several billion-dollar markets, combining organic growth with selective, accretive acquisitions to strengthen its competitive position.

Average Trading Volume: 311,951

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$565.1M

Learn more about CL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1